GMP compliance Corona vaccine production

GMP compliance Corona vaccine production


currently available at UDEMY:


Get experience of GMP compliance tools to receive authorial approval for drug manufacturing. Training will be based on theoretical approach for upcoming large

scale Corona vaccine production in Germany.

More details

24,99 € tax incl.


Recently BioNTech has acquired Novartis plant in Marburg for large scale manufacturing of Corona vaccines [1]. This current approach represents innovative but also risky procedure since vaccine candidate must be approved and production line must be inspected by authority.

In order to receive authorial permission to produce this vaccine, several things must be performed to establish GMP compliance. These aspects are then subject of authorial inspection representing prerequisite for receiving manufacturing license in Germany.

In this seminar you will learn all relevant issues to qualify a production plant for pharmaceuticals based on this prominent case study for large scale mRNA vaccine manufacturing. This theoretical approach will illustrate authorial requirements for pharma production and general drug approval.


Teaching goals :

  • approval of pharmaceuticals (vaccines) in Germany and EU

  • clinical trials and GCP compliance

  • from pilot scale to large scale

  • qualification of large scale production to GMP compliance (vaccines)




No products

Shipping 0,00 €
Total 0,00 €

Cart Check out